Clinical trialNCT05835466RecruitingPhase 2Interventional

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

SponsorIcahn School of Medicine at Mount SinaiEnrollment10Myelofibrosis (PMF)Post Essential Thrombocythemia Myelofibrosis (ET-MF)Post Polycythemia Vera Related Myelofibrosis (PV-MF)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor (JAKi). 26 patients will be enrolled. Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study period of 6 cycles (24 weeks). After cycle 6, patients may continue receiving reparixin once daily on a 4-week cycle if at least stable disease (SD) is met by IWG-MRT criteria until loss of response, disease progression, unacceptable toxicity, patient/physician withdrawal, or termination of study by sponsor.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Aaron Gerds, MD, MS
Cleveland Clinic Taussig Cancer Institute
Study Chair
clinicaltrials.gov ↗
Marina Kremyanskaya, PhD, MD
Icahn School of Medicine at Mount Sinai
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Moffitt Cancer Center
Tampa, Florida, United States
Andrew Kuykendall, MD
Recruiting
Emory University
Atlanta, Georgia, United States
Anthony Hunter, MD
Recruiting
Roswell Park Cancer Institute
Buffalo, New York, United States
Eunice Wang, MD
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Brian Chernak, MD
Recruiting
Newyork-Presbyterian/weill Cornell Medical Center
New York, New York, United States
Ghaith Abu-Zeinah, MD
Recruiting
Ruttenberg Treatment Center
New York, New York, United States
Marina Kremyanskaya
Recruiting
Wake Forest Baptist Health Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
Rupali Bhave, MD
Recruiting
the Cleveland Clinic Foundation
Cleveland, Ohio, United States
Aaron Gerds, MD
Recruiting
the Ohio State University
Columbus, Ohio, United States
Shivani Handa, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Reparixin

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Jul 2023
Primary completion: 31 Dec 2027
Completion: 1 Dec 2028
Last update posted: 6 May 2026
Registered enrollment: 10
Registry id: NCT05835466

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.